AIM:DEST

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Market Cap

UK£76.2m

Last Updated

2021/06/17 21:55 UTC

Data Sources

Company Financials +

Executive Summary

Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of medicines for the treatment of infectious diseases in the United Kingdom. More Details


Snowflake Analysis

Flawless balance sheet and overvalued.

Share Price & News

How has Destiny Pharma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: DEST is more volatile than 75% of UK stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: DEST's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of UK stocks.


Market Performance


7 Day Return

-3.6%

DEST

-0.2%

GB Biotechs

0.7%

GB Market


1 Year Return

222.2%

DEST

38.4%

GB Biotechs

19.0%

GB Market

Return vs Industry: DEST exceeded the UK Biotechs industry which returned 38.4% over the past year.

Return vs Market: DEST exceeded the UK Market which returned 19% over the past year.


Shareholder returns

DESTIndustryMarket
7 Day-3.6%-0.2%0.7%
30 Day-7.5%2.7%2.1%
90 Day-17.6%-1.4%7.1%
1 Year222.2%222.2%38.8%38.4%25.0%19.0%
3 Year16.7%16.7%26.7%24.9%14.6%1.4%
5 Yearn/a80.6%77.0%49.0%21.0%

Long-Term Price Volatility Vs. Market

How volatile is Destiny Pharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Destiny Pharma undervalued compared to its fair value and its price relative to the market?

6.12x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate DEST's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate DEST's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: DEST is unprofitable, so we can't compare its PE Ratio to the European Biotechs industry average.

PE vs Market: DEST is unprofitable, so we can't compare its PE Ratio to the UK market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate DEST's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: DEST is good value based on its PB Ratio (6.1x) compared to the GB Biotechs industry average (6.6x).


Future Growth

How is Destiny Pharma forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

24.0%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if DEST's forecast earnings growth is above the savings rate (0.9%).

Earnings vs Market: Insufficient data to determine if DEST's earnings are forecast to grow faster than the UK market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if DEST's revenue is forecast to grow faster than the UK market.

High Growth Revenue: DEST is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if DEST's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Destiny Pharma performed over the past 5 years?

-26.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: DEST is currently unprofitable.

Growing Profit Margin: DEST is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: DEST is unprofitable, and losses have increased over the past 5 years at a rate of 26.5% per year.

Accelerating Growth: Unable to compare DEST's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: DEST is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (21.8%).


Return on Equity

High ROE: DEST has a negative Return on Equity (-43.51%), as it is currently unprofitable.


Financial Health

How is Destiny Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: DEST's short term assets (£11.4M) exceed its short term liabilities (£1.3M).

Long Term Liabilities: DEST has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: DEST is debt free.

Reducing Debt: DEST has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: DEST has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: DEST has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 29.8% each year.


Dividend

What is Destiny Pharma current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate DEST's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate DEST's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if DEST's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if DEST's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of DEST's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.8yrs

Average management tenure


CEO

Neil Clark (57 yo)

4.17yrs

Tenure

UK£325,000

Compensation

Mr. Neil Robert Clark, BSc, FCA, has been the Chief Executive Officer and Executive Director at Destiny Pharma plc since April 13, 2017 and January 20, 2017 respectively. Mr. Clark has been Consultant of P...


CEO Compensation Analysis

Compensation vs Market: Neil's total compensation ($USD452.87K) is above average for companies of similar size in the UK market ($USD329.30K).

Compensation vs Earnings: Neil's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: DEST's management team is considered experienced (2.8 years average tenure).


Board Members

Experienced Board: DEST's board of directors are considered experienced (3.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: DEST insiders have sold more shares than they have bought in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 36.5%.


Top Shareholders

Company Information

Destiny Pharma plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Destiny Pharma plc
  • Ticker: DEST
  • Exchange: AIM
  • Founded: 1996
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£76.174m
  • Shares outstanding: 59.86m
  • Website: https://www.destinypharma.com

Number of Employees


Location

  • Destiny Pharma plc
  • Sussex Innovation Centre
  • Unit 36
  • Brighton
  • East Sussex
  • BN1 9SB
  • United Kingdom

Listings


Biography

Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of medicines for the treatment of infectious diseases in the United Kingdom. The company is involve...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/06/17 21:55
End of Day Share Price2021/06/17 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.